Protocol Ledger

NCT06943755 · Phase II/III · RECRUITING

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Interventional Phase II/III clinical trial protocol NCT06943755 sponsored by Exelixis in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-07-21 Enrollment: 440 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06943755
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)440 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06943755
Protocol FieldVerified Registry Value
NCT IdentifierNCT06943755
Consolidated Lead SponsorExelixis
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment440 participants (ESTIMATED)
Registered Start Date2025-07-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI